Medartis Holding AG (MED) - Net Assets
Based on the latest financial reports, Medartis Holding AG (MED) has net assets worth CHF275.87 Million CHF (≈ $348.78 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF559.92 Million ≈ $707.89 Million USD) and total liabilities (CHF284.05 Million ≈ $359.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medartis Holding AG strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF275.87 Million |
| % of Total Assets | 49.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | 23.16% |
| 10-Year Change | 1512.85% |
| Growth Volatility | 370.18 |
Medartis Holding AG - Net Assets Trend (2014–2025)
This chart illustrates how Medartis Holding AG's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see MED market cap overview.
Annual Net Assets for Medartis Holding AG (2014–2025)
The table below shows the annual net assets of Medartis Holding AG from 2014 to 2025. Also explore Medartis Holding AG equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF275.87 Million ≈ $348.78 Million |
+2.31% |
| 2024-12-31 | CHF269.65 Million ≈ $340.91 Million |
+5.76% |
| 2023-12-31 | CHF254.96 Million ≈ $322.34 Million |
+7.23% |
| 2022-12-31 | CHF237.78 Million ≈ $300.62 Million |
+6.15% |
| 2021-12-31 | CHF224.00 Million ≈ $283.19 Million |
+5.14% |
| 2020-12-31 | CHF213.04 Million ≈ $269.33 Million |
-1.18% |
| 2019-12-31 | CHF215.57 Million ≈ $272.54 Million |
-1.22% |
| 2018-12-31 | CHF218.23 Million ≈ $275.91 Million |
+1180.84% |
| 2017-12-31 | CHF17.04 Million ≈ $21.54 Million |
-0.39% |
| 2016-12-31 | CHF17.10 Million ≈ $21.62 Million |
+136.43% |
| 2015-12-31 | CHF-46.95 Million ≈ $-59.36 Million |
+13.47% |
| 2014-12-31 | CHF-54.26 Million ≈ $-68.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medartis Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4725160400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF2.73 Million | 0.99% |
| Other Comprehensive Income | CHF281.57 Million | 102.06% |
| Total Equity | CHF275.87 Million | 100.00% |
Medartis Holding AG Competitors by Market Cap
The table below lists competitors of Medartis Holding AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cansino Biologics Inc
SHG:688185
|
$1.06 Billion |
|
AS LHV GROUP EO -10
F:ASU0
|
$1.06 Billion |
|
Cangzhou Mingzhu Plastic Co Ltd
SHE:002108
|
$1.06 Billion |
|
Boai NKY Pharmaceuticals Ltd
SHE:300109
|
$1.06 Billion |
|
Jiangsu Zongyi Co Ltd
SHG:600770
|
$1.06 Billion |
|
Changsha DIALINE New Material Sci & Tech Co Ltd
SHE:300700
|
$1.06 Billion |
|
Sinar Mas Agro Resources and Technology Tbk PT
JK:SMAR
|
$1.06 Billion |
|
SK Reit Co Ltd
KO:395400
|
$1.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medartis Holding AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 269,646,000 to 275,872,000, a change of 6,226,000 (2.3%).
- Net income of 8,349,000 contributed positively to equity growth.
- New share issuances of 709,000 increased equity.
- Other comprehensive income decreased equity by 4,896,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF8.35 Million | +3.03% |
| Share Issuances | CHF709.00K | +0.26% |
| Other Comprehensive Income | CHF-4.90 Million | -1.77% |
| Other Changes | CHF2.06 Million | +0.75% |
| Total Change | CHF- | 2.31% |
Book Value vs Market Value Analysis
This analysis compares Medartis Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | CHF-4.00 | CHF82.30 | x |
| 2016-12-31 | CHF1.46 | CHF82.30 | x |
| 2017-12-31 | CHF1.45 | CHF82.30 | x |
| 2018-12-31 | CHF20.53 | CHF82.30 | x |
| 2019-12-31 | CHF18.36 | CHF82.30 | x |
| 2020-12-31 | CHF18.10 | CHF82.30 | x |
| 2021-12-31 | CHF18.98 | CHF82.30 | x |
| 2022-12-31 | CHF20.09 | CHF82.30 | x |
| 2023-12-31 | CHF20.84 | CHF82.30 | x |
| 2024-12-31 | CHF21.74 | CHF82.30 | x |
| 2025-12-31 | CHF22.17 | CHF82.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medartis Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.10%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 2.03x
- Recent ROE (3.03%) is above the historical average (2.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 8.83% | 0.80x | 0.00x | CHF11.97 Million |
| 2016 | 19.38% | 3.58% | 0.80x | 6.74x | CHF1.60 Million |
| 2017 | 5.09% | 0.82% | 0.80x | 7.66x | CHF-837.31K |
| 2018 | 1.93% | 3.46% | 0.47x | 1.17x | CHF-17.62 Million |
| 2019 | 1.00% | 1.65% | 0.45x | 1.34x | CHF-19.41 Million |
| 2020 | -0.44% | -0.74% | 0.45x | 1.33x | CHF-22.25 Million |
| 2021 | 3.05% | 4.28% | 0.54x | 1.33x | CHF-15.56 Million |
| 2022 | -2.43% | -3.16% | 0.56x | 1.38x | CHF-29.56 Million |
| 2023 | 0.24% | 0.29% | 0.61x | 1.37x | CHF-24.88 Million |
| 2024 | 1.31% | 1.57% | 0.49x | 1.71x | CHF-23.44 Million |
| 2025 | 3.03% | 3.10% | 0.48x | 2.03x | CHF-19.24 Million |
Industry Comparison
This section compares Medartis Holding AG's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $724,070,667
- Average return on equity (ROE) among peers: 1.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medartis Holding AG (MED) | CHF275.87 Million | 0.00% | 1.03x | $1.06 Billion |
| Kuros Biosciences AG (KURN) | $74.01 Million | -38.48% | 0.11x | $720.86 Million |
| Medacta Group SA (MOVE) | $226.40 Million | 22.76% | 1.16x | $2.79 Billion |
| Sonova H Ag (SOON) | $1.87 Billion | 19.23% | 0.44x | $12.20 Billion |
About Medartis Holding AG
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company's medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides products for the hand, wrist, forearm, elbow, shoulder, and foot and ankle, a… Read more